Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epivir (3TC) Clear all
Terminated Phase 2 Interventional

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

NCT00040157
View directory record Official record
Conditions
HIV Infections
Interventions
ACH126-443 (Beta-L-Fd4C)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 3, 2026, 3:52 AM EDT
Not listed Phase 4 Interventional

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00005000
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
View directory record Official record
Conditions
HIV Infections
Interventions
TRIUMEQ, DOVATO
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

NCT03272347
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 2 Interventional

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Oct 3, 2026, 3:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 3, 2026, 3:52 AM EDT
Withdrawn Phase 2 Interventional

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

NCT00001094
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Menlo Park, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

NCT00336778
View directory record Official record
Conditions
HIV Infections
Interventions
3TC, TDF, NLV
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

3TC (Lamivudine; GR109714X) Open-Label Program

NCT00002108
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00004855
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Abacavir sulfate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

NCT01263015
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
55
States / cities
Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

NCT00035633
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 3, 2026, 3:52 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

NCT01528865
View directory record Official record
Conditions
Lymphoma
Interventions
Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002407
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

NCT00099359
View directory record Official record
Conditions
Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions
Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 2 Days
Enrollment
1,735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
5
States / cities
Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 2 Interventional

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

NCT00001067
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Zidovudine and Lamivudine Given Once Versus Twice Daily

NCT00014014
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

NCT00004583
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
42
States / cities
Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

NCT00002215
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Nelfinavir mesylate
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 3:52 AM EDT
Not listed Phase 4 Interventional

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00011895
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

NCT00000901
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 3, 2026, 3:52 AM EDT